EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Optimizing cardiovascular health: a systematic review and meta-analysis of olezarsen dosages in high-risk hypertriglyceridemic patients

Ibrahim Serag, Ibraheem M Alkhawaldeh, Ayed A Shati, Youssef A Alqahtani, Ahmed Alattar, Sara Ahmad Khader Alkhamaiseh, Mostafa Hossam El Din Moawad

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026

DOI: 10.1007/s00210-025-04406-2 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Ibrahim Serag und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Mansoura University, Mansoura, Egypt. Ibrahimserag@std.mans.edu.eg. Hauptthemen laut MEDLINE: Hypertriglyceridemia, Cardiovascular Diseases, Oligonucleotides, Antisense. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Hypertriglyceridemia and hypercholesterolemia are well-known risk factors for atherosclerotic cardiovascular disease (ASCVD), especially in patients already at elevated cardiovascular risk. Despite current treatment approaches, including lifestyle changes and medication, many individuals do not reach ideal lipid levels, emphasizing the need for new therapeutic options. Olezarsen, an antisense oligonucleotide targeting apolipoprotein C-III (ApoC-III) synthesis, has emerged as a promising candidate to reduce residual cardiovascular risk in these patients. AIM: This systematic review and meta-analysis aimed to assess the effectiveness and safety of different dosages of Olezarsen in patients with high-risk hypertriglyceridemia. Additionally, it explored whether varying dosage regimens impacted lipid outcomes and adverse events. METHODS: Following PRISMA guidelines, a comprehensive search was conducted in PubMed, Scopus, Web of Science, and Cochrane Library for randomized controlled trials (RCTs) published in English. The studies included compared different doses of Olezarsen with placebo in high-risk hypertriglyceridemia patients. Primary outcomes were changes in triglycerides (TG), very-low-density lipoprotein cholesterol (VLDL-C), apolipoprotein B (ApoB), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and treatment-emergent adverse events (TEAE). Secondary outcomes included changes in non-HDL-C and total cholesterol (TC). The data were analyzed as mean differences (MD) or odds ratios (OR) using a random-effects model. RESULTS: Four RCTs (309 participants) were included. The pooled analysis demonstrated significant reductions in TG (MD = -76.11), VLDL-C (MD = -54.95 mg/dL), ApoB (MD = -12.40 mg/dL), non-HDL-C (MD = -18.03 mg/dL), and LDL-C (MD = -10.09 mg/dL) with Olezarsen treatment compared to placebo. Olezarsen also significantly increased HDL-C levels (MD = + 22.60 mg/dL), while total cholesterol remained unchanged. No significant differences in overall adverse events or drug-related adverse events were observed compared to placebo. Subgroup analysis revealed a dose-dependent effect on several lipid parameters without an increase in adverse events with higher doses. CONCLUSION: Olezarsen effectively improves key lipid parameters, including TG, VLDL-C, ApoB, non-HDL-C, and LDL-C, while also safely raising HDL-C in patients with high-risk hypertriglyceridemia. Total cholesterol remained stable, and no increase in adverse events was noted. Further studies are needed to determine optimal dosing and long-term cardiovascular benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertriglyceridemiaCardiovascular DiseasesOligonucleotides, AntisenseHumansApolipoprotein C-IIITriglyceridesDose-Response Relationship, DrugRandomized Controlled Trials as TopicHeart Disease Risk Factors

Stichwörter der Autor:innen

Antisense OligonucleotideApoC-IIIHigh Cardiovascular RiskHypertriglyceridemiaLipid ManagementMeta-AnalysisOlezarsenRandomized Controlled Trial

Substanzen

Oligonucleotides, AntisenseApolipoprotein C-IIITriglycerides

Autor:innen und Institutionen

  • Faculty of Medicine, Mansoura University, Mansoura, Egypt. Ibrahimserag@std.mans.edu.eg.
  • Faculty of Medicine, Mutah University, Al-Karak, Jordan.
  • Department of Child Health, College of Medicine, King Khalid University, Abha, Saudi Arabia.
  • Alexandria Main University Hospital, Alexandria, Egypt.
  • Faculty of Medicine, Suez Canal University, Ismailia, Egypt.

Zitieren

APA

Serag, I., Alkhawaldeh, I. M., Shati, A. A., Alqahtani, Y. A., Alattar, A., Khader Alkhamaiseh, S. A., & Moawad, M. H. E. D. (2026). Optimizing cardiovascular health: a systematic review and meta-analysis of olezarsen dosages in high-risk hypertriglyceridemic patients. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04406-2

Vancouver

Serag I, Alkhawaldeh IM, Shati AA, Alqahtani YA, Alattar A, Khader Alkhamaiseh SA, et al. Optimizing cardiovascular health: a systematic review and meta-analysis of olezarsen dosages in high-risk hypertriglyceridemic patients. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-025-04406-2

BibTeX
@article{Serag2026,
  author = {Serag, Ibrahim and Alkhawaldeh, Ibraheem M and Shati, Ayed A and Alqahtani, Youssef A and Alattar, Ahmed and Khader Alkhamaiseh, Sara Ahmad and Moawad, Mostafa Hossam El Din},
  title = {Optimizing cardiovascular health: a systematic review and meta-analysis of olezarsen dosages in high-risk hypertriglyceridemic patients},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-025-04406-2}
}
Kostenlos starten →